Article

A biomarker for chemoprevention

Author(s):

One of the hardest truths about lung cancer is that so many people who've kicked the smoking habit will still develop lung cancer. "Half the lung cancer cases in the United States are people who are former smokers," said Paul Bunn Jr., MD, executive director of the International Association for the Study of Lung Cancer.Bunn, who is also a researcher at the University of Colorado Cancer Center, spoke April 2 at a press conference during the annual meeting of the American Association for Cancer Research in Orlando.Lung cancer is the leading cause of cancer death in men and women in the U.S., as well as the leading cause of cancer death worldwide. The five-year survival rate is 15 percent because patients often present with late-stage disease that is not treatable by current therapies.Although people who quit smoking remain at risk of developing lung cancer, "we need to repair their lungs through chemoprevention," Bunn said.Bunn presented an update on a multicenter, double-blind, placebo-controlled phase 2 study that tested the effect of iloprost, used primarily to treat pulmonary arterial hypertension, on 152 former smokers who had endobronchial dysplasia. Iloprost is similar to a hormone called prostacyclin, which is produced in the lungs and keeps the blood vessels relaxed, according to mayoclinic.com. Most patients with non-small cell lung cancer (NSCLC) have decreased levels of prostacyclin. A pre-clinical study using transgenic mice exposed to cigarette smoke showed that iloprost prevented lung cancer.Bunn said results of the current study were significant because they identified a biomarker for measuring the success of lung cancer chemoprevention.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Imiage of two doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Related Content